BioLineRx posts positive Phase 1a results in neuropathic pain

Final results of a Phase 1a study of BioLineRx’s (NASDAQ, TASE:BLRX) BL-1021 small molecule for neuropathic pain demonstrated that a single administration of BL-1021 in the dose range examined was safe and well tolerated, with no significant changes in vital signs, ECG or laboratory safety parameters at any dose when compared either to baseline measurements [...]

ThinkEquity starts Synta Pharma at buy

ThinkEquity has initiated coverage of Synta Pharmaceuticals (NASDAQ:SNTA) with a “buy” rating and 12-month price target of $6, predicting that ganetespib, Synta’s lead Hsp90 inhibitor, will “potentially demonstrate efficacy in a subset of lung cancer and can likely generate peak sales of approximately $450 million to $500 million, if approved.” The stock closed at $3.55 [...]

Rodman starts Celsion at market outperform

Rodman & Renshaw has initiated coverage of Celsion (NASDAQ:CLSN) with a “market outperform/speculative risk” rating and a target price of $6, based on a discounted revenues and earnings per share valuation methodology. The stock closed at $2.75 on Tuesday. “With approximately $25 million in cash pro forma, and an enterprise value of $47 million, we [...]

Roth ups AtriCure target to $15

Roth Capital Partners has raised its target price on AtriCure (NASDAQ:ATRC) to $15 from $13.50, heading into the company’s FDA advisory panel meeting. The stock was quoted at $11.80 Monday afternoon. “While FDA panel votes are difficult to predict, we view AtriCure’s risk-reward as positive and believe a positive recommendation would have major strategic implications [...]

Canaccord Genuity conference top picks

Canaccord Genuity has issued a report of its top picks – two value ideas and four growth ideas – coming out of its 31st annual Global Growth conference held last week in Boston. “While the overall equities markets’ direction may be a source of uncertainty in the near-term, we found our companies steadfastly holding to [...]

Ventrus begins first pivotal trial in hemorrhoids

Ventrus BioSciences (NASDAQ:VTUS) has opened enrollment at 65 of the 70 sites that will participate in the first Phase 3 trial of VEN 309 for the treatment of symptomatic hemorrhoids. Ventrus expects that the dosing of the first patients will begin next week and that the remaining five sites will be initiated in the current [...]

Angiotech coming off NASDAQ Jan. 13

Shares of Angiotech Pharmaceuticals (TSX:ANP; NASDAQ:ANPI) will be delisted from NASDAQ on Jan. 13 because the company failed to regain compliance with the exchange’s listing requirements within a 180-day grace period that ended last Monday. The company said it will not request a hearing as part of NASDAQ’s appeal process. Angiotech’s common shares will continue [...]

Dundee upgrades YM to “buy, venture risk”

Dundee Securities has upgraded YM BioSciences (TSX:YM; Amex:YMI) to “buy, venture risk” from “under review” based on the growing focus of JAK-1/2 inhibitors and the potential that may exist to differentiate YM’s CYT387 drug candidate in the space. Analyst David Martin writes that YM’s release of early data this week “suggests that CYT387 may provide [...]

IMRIS to list on Nasdaq and sell stock

IMRIS (TSX:IM) has filed a registration statement as part of an IPO in the U.S. and has received conditional approval to list its common shares on the NASDAQ Global Market under the symbol IMRS. IMRIS proposes to offer 10 million common shares and certain selling shareholders propose to offer 3.7 million shares through a syndicate [...]

Tekmira in 1-for-5 stock consolidation

Tekmira Pharmaceuticals (TSX:TKM) is consolidating its common stock on a one-for-five basis in order to meet listing requirements on the Nasdaq Stock Market, with the goal of listing on Nasdaq the week of Nov. 15, 2010. Tekmira will have 10,337,414 common shares outstanding after the consolidation. The stock will begin trading on a post-consolidated basis [...]

« Previous Page — Next Page »